Detailansicht

Wissensnetz

Person

Martin J. Van den Bent

Onkologe

Name	Martin J. Van den Bent
Ort	Niederlande
Beruf	Onkologe (charakteristischer Beruf)
Variante	Martin J. van den Bent M. J. van den Bent
Weitere Angaben	Neuro-Oncology Unit, Brain Tumour Centre at Erasmus MC Cancer Institute, Rotterdam, Netherlands
Datensatztyp	Person
GND-Nummer	1162295198
Datensatz-ID	1162295198
Beteiligt an alle anzeigen ESTRO-EANO guideline on target delineation and radiotherapy for IDHmutant WHO CNS grade 2 and 3 diffuse glioma Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0 IDH inhibition in gliomas: from preclinical models to clinical trials Cognition and health-related quality of life in long-term survivors of high-grade glioma: an interactive perspective from patient and caregiver Independent prognostic impact of DNA methylation class and chromosome 1p loss in WHO grade 2 and 3 meningioma undergoing adjuvant high-dose radiotherapy: comprehensive molecular analysis of EORTC 22042–26042 Impact of timing of antiseizure medication withdrawal on seizure recurrence in glioma patients: a retrospective observational study Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers Medulloblastoma in adults: evaluation of the Dutch society for neuro-oncology treatment protocol Study protocol of the GLOW study: maximising treatment options for recurrent glioblastoma patients by whole genome sequencing-based diagnostics—a prospective multicenter cohort study DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome—including in elderly patients Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial The effectiveness of antiepileptic drug treatment in glioma patients: lamotrigine versus lacosamide Effect of antiepileptic drugs in glioma patients on self-reported depression, anxiety, and cognitive complaints MMSE is an independent prognostic factor for survival in primary central nervous system lymphoma EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033 Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification Does early resection of presumed low-grade glioma improve survival? A clinical perspective Joint modeling of longitudinal health-related quality of life data and survival Withdrawal of antiepileptic drugs in glioma patients after long-term seizure freedom: design of a prospective observational study Interlaboratory comparison of IDH mutation detection Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial Glial fibrillary acidic protein and its fragments discriminate astrocytoma from oligodendroglioma

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Martin J. Van den Bent

ESTRO-EANO guideline on target delineation and radiotherapy for IDHmutant WHO CNS grade 2 and 3 diffuse glioma

Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0

IDH inhibition in gliomas: from preclinical models to clinical trials

Cognition and health-related quality of life in long-term survivors of high-grade glioma: an interactive perspective from patient and caregiver

Independent prognostic impact of DNA methylation class and chromosome 1p loss in WHO grade 2 and 3 meningioma undergoing adjuvant high-dose radiotherapy: comprehensive molecular analysis of EORTC 22042–26042

Impact of timing of antiseizure medication withdrawal on seizure recurrence in glioma patients: a retrospective observational study

Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers

Medulloblastoma in adults: evaluation of the Dutch society for neuro-oncology treatment protocol

Study protocol of the GLOW study: maximising treatment options for recurrent glioblastoma patients by whole genome sequencing-based diagnostics—a prospective multicenter cohort study

DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome—including in elderly patients

Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial

The effectiveness of antiepileptic drug treatment in glioma patients: lamotrigine versus lacosamide

Effect of antiepileptic drugs in glioma patients on self-reported depression, anxiety, and cognitive complaints

MMSE is an independent prognostic factor for survival in primary central nervous system lymphoma

EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood

cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas

A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma

Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma

Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics

Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma

The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033

Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification

Does early resection of presumed low-grade glioma improve survival? A clinical perspective

Joint modeling of longitudinal health-related quality of life data and survival

Withdrawal of antiepileptic drugs in glioma patients after long-term seizure freedom: design of a prospective observational study

Interlaboratory comparison of IDH mutation detection

Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial

Glial fibrillary acidic protein and its fragments discriminate astrocytoma from oligodendroglioma